HEM Stock Discussion
Hemostemix Inc. Description
Hemostemix Inc is a Canada-based clinical-stage biotechnology company. The Company's principal business is to develop, manufacture and commercialize blood-derived cell therapies for medical conditions, including critical limb ischemia (CLI). The Company's clinical-stage candidate, ACP-01, is an autologous cell therapy for the treatment of CLI. ACP-01 is in a Phase II clinical trial in Canada, South Africa and the United States. The Company also focuses on developing other cell products, such as bone cell precursors (BCPs), myocardial cell precursors (MCPs) and neural cell precursors (NCPs). It operates in Canada and Israel. The Company has approximately 2,200 square foot research and manufacturing facility in Ness Ziona, Israel. Hemostemix Limited is the subsidiary of the Company.
Industry: Biotechnology
Keywords: Manufacturing Nature Clinic Biotechnology Therapy Biology Clinical Trial Bone Hypertension Cell Biology Stem Cells Cell Products Cell Therapy Manufacturing Facility
Recent Comments
- TraderMike on Canadian Depositary Receipts
- Cos3 on Canadian Depositary Receipts
- TraderMike on Canadian Depositary Receipts
- TraderMike on Canadian Depositary Receipts
- Cos3 on Canadian Depositary Receipts
From the Blog
Popular Now
Featured Articles